

**Supplementary Table 1: Summary of patient characteristics in total**

		CON	CD	UC
<b>Number Patients</b>		61	120	118
<b>Number Samples</b>		135	183	194
<b>Age (Ø, range)</b>		28 (18-44)	39 (18-75)	45 (18-82)
<b>Female [%]</b>		68.1	56.3	45.9
<b>HBI (Ø, range)</b>			5.0 (0-25)	
<b>Mayo c.s. (Ø, range)</b>				2.1 (0-11)
<b>Therapy [%]</b>	<i>Aminosalicylates</i>		19.6	41.3
	<i>Steroids</i>		21.2	37.6
	<i>Immunosuppressants</i>		3.2	1.6
	<i>Anti-TNF antibodies</i>		37.0	23.8
	<i>Vedolizumab</i>		48.7	68.8
	<i>Ustekinumab</i>		6.9	0.5
<b>Disease localization [%]</b>		L1: 19.2	E1: 24.3	
		L2: 14.7	E2: 23.7	
		L3: 45.2	E3: 52.0	
		L4: 0.0		
		L4+: 20.9		